Bioinformatics Analysis of Merkel Cell Carcinoma to identify critical genes and their validation

  • Himanshu Kumar
  • Yasha Hasija

Abstract

Merkel Cell Carcinoma (MCC) is a destructive form of neuroendocrine carcinoma that represents the 2nd highest cause of skin cancer related deaths despite being a relatively rare form of cancer. Different risk factors have been associated with MCC such as advancement age, immunosuppression, and ultraviolet light exposure, polyomavirus infection and a current, concurrent or previous diagnosis of Chronic Lymphocytic Leukaemia (CLL). However, the exact mechanism that leads to MCC and its inherent biology is yet to be fully researched and explored. The current treatments for MCC are a combination of surgery and radiation or chemo-radiation. So far, only two drugs have been approved by FDA for the treatment of MCC, with both drugs being immune checkpoint inhibitors. However, the drug approval from FDA was accelerated based on promising results from a relatively small number of patients, which means that the more research and trials are undergoing currently considering the fact that a very small cohort was used for clinical trials. Presently there are no biomarkers indicative of MCC and additional research is essential. With the advent of bioinformatics and microarray technology, in silico approaches pertaining to ‘omics’ data analysis, shall allow identification of hub genes and miRNA to broaden our understanding of MCC biology and their clinical utility.

Keywords: Merkel Cell Carcinoma, Microarray, Bioinformatics Analysis, Gene Analysis

Downloads

Download data is not yet available.

References

[1] Schadendorf D, Lebbe C, Zur Hausen A, et al. (2017). Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer, 71, 53–69.
[2] Tang CK, Toker C. (1978). Trabecular carcinoma of the skin: an ultrastructural study. Cancer, 42(5), 2311–21.
[3] Kaae J, Hansen AV, Biggar RJ, Boyd HA, Moore PS, Wohlfahrt J, et al. (2010). Merkel cell carcinoma: incidence, mortality, and risk of other cancers. J Natl Cancer Inst, 102 (11), 793-801.
[4] Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. (2016). Avelumab in patients with chemotherapy refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial. Lancet Oncol, 17(10), 1374–85.
[5] Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. (2016). PD-1 blockade with Pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med, 374(26), 2542–52.
[6] Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, Tan W, Nandy D, Bevan GH, Longenbach S, Sun Z, Lu Y,Wang T, Thibodeau SN, Boardman L, Kohli M, Wang L. (2014). Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol, 67(1), 3-41.
[7] Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, Jensen LJ, Mering CV. (2019). STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res., 47(D1):D607-D613.
[8] Bader GD, Hogue CW. (2003). An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics, 13; 4:2.
[9] Aytes, Alvaro et al. “Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy.” Cancer cell vol. 25,5 (2014): 638-651. doi:10.1016/j.ccr.2014.03.017.
[10] Becker JC. Merkel cell carcinoma. (2010). Ann Oncol, 21(7), 81–85.
[11] Burack J, Altschuler EL. (2003). Sustained remission of metastatic Merkel cell carcinoma with treatment of HIV infection. J R Soc Med. 9(6), 238–239. doi: 10.1258/jrsm.96.5.238.
[12] Mariot P, Vanoverberghe K, Lalevee N, Rossier MF & Prevarskaya N. (2002). Overexpression of an alpha 1H (CaV3.2) T-type calcium channel during neuroendocrine differentiation of human prostate cancer cells. J. Biol. Chem, 277(13), 10824–10833.
Statistics
0 Views | 0 Downloads
How to Cite
Kumar, H., & Hasija, Y. (2021). Bioinformatics Analysis of Merkel Cell Carcinoma to identify critical genes and their validation. Asian Journal For Convergence In Technology (AJCT) ISSN -2350-1146, 7(2), 19-24. https://doi.org/10.33130/AJCT.2021v07i02.004